UP 421
Alternative Names: HIP-pancreatic islet cell therapy - Sana Biotechnology; UP-421Latest Information Update: 30 Jun 2025
At a glance
- Originator Sana Biotechnology
- Class Antihyperglycaemics; Gene therapies; Induced pluripotent stem cell therapies
- Mechanism of Action HLA antigen modulators; Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Type 1 diabetes mellitus
Most Recent Events
- 23 Jun 2025 Pharmacodynamics and adverse events data from a phase I trial in Type 1 diabetes released by Sana Biotechnology
- 07 Jan 2025 Pharmacodynamics and adverse events data from a phase I trial in Type 1 diabetes released by Sana Biotechnology
- 09 Sep 2024 Efficacy and adverse event data from Type 1 diabetes mellitus presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD-2024)